Drug
Pm1003
Pm1003: highest development phase Phase 1/2, developed by BioNTech. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- BioNTech
Trials
| Drug | Phase | Indication |
|---|---|---|
| PM1003 Injection NCT05862831 | Phase 1/2 | Advanced Solid Tumors |
Latest
No recent events.
Follow Pm1003 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.